A number of experimental studies suggest that Ninj1, an adhesion molecule, regulates macrophage migration, cell-to-cell/cell-to-matrix adhesion, and activation, and thus it can be used as a therapeutic target of diverse inflammatory diseases including experimental autoimmune encephalomyelitis [41,42], colitis [43], diabetes [44], and atherosclerosis [45]. Here, NINJ1 is linked to experimental autoimmune encephalomyelitis.